Sign in
4

Changes in Ownership

Trevi Therapeutics, Inc. Filed Acc 0001209191-23-017148

Chief Commercial Officer acquired 18,750 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

Simon Farrell · Chief Commercial Officer

Table I: Non-derivative

1 line
Date Transaction Shares Price Value Owned after D/I
2023-03-07 Exercise or conversion : show line 1 in the form +18,750 $0.51 $9,581 39,400 D

Table II: Derivative

1 line
Date Transaction Shares Owned after D/I
2023-03-07 Exercise or conversion : show line 2 in the form Stock Option (right to buy) −18,750 56,250 D
Loading xslF345X03/doc4.xml…